All data are based on the daily closing price as of September 6, 2024
o
Oscotec
039200.KQ
25.52 USD
-1.10
-4.13%
Overview
Last close
25.52 usd
Market cap
717.07M usd
52 week high
31.92 usd
52 week low
14.04 usd
Target price
31.03 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
280.6802
Price/Book Value
14.8209
Enterprise Value
904.18M usd
EV/Revenue
261.8426
EV/EBITDA
-32.8386
Key financials
Revenue TTM
3.63M usd
Gross Profit TTM
1.32M usd
EBITDA TTM
-19.18M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
122.64B usd
Net debt
N/A usd
About
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.